ImmunoGen, Inc.
_________________________________________________________________________________
ImmunoGen, Inc. Financial Snapshot
Operating Performance
Fast Facts
830 Winter Street, Waltham, 02139,United The company reported revenue of US$19 million
Headquarters Address
States of America during the fiscal year 2011 (2011). The company's
revenue declined at a compounded rate of 15.69%
Telephone + 1 781 8950600
during 2007–2011, with an annual growth of 38.46%
over 2010. In 2011, the company recorded an
Fax + 1 781 8950611 operating margin of -311.77%, as against -367.46% in
2010.
Website www.immunogen.com
Ticker Symbol, Stock Exchange IMGN, NASDAQ Revenue and Margins
Number of Employees 245
Fiscal Year End June
Revenue (in US$ million) 19
SWOT Analysis
Strengths Weaknesses
Focused research and development
Declining operational performance
(R&D)
Proprietary TAP technology Weakening liquidity position
Significant partnerships
Strong liquidity position
Opportunities Threats
Increase in healthcare spending Healthcare costs
Positive outlook for the global
Intense competition
pharmaceutical industry
Strategic agreements Uncertain R&D outcome
___________________________________________________________________________________________
ImmunoGen, Inc. - SWOT Profile Page 1
ImmunoGen, Inc.
_________________________________________________________________________________
TABLE OF CONTENTS
1 Business Analysis ................................................................................................................................... 5
1.1 Company Overview ......................................................................................................................................... 5
1.2 Business Description ....................................................................................................................................... 5
1.3 Major Products and Services ........................................................................................................................... 6
2 Analysis of Key Performance Indicators ............................................................................................... 7
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators ....................................... 7
2.2 Key Financial Performance Indicators .............................................................................................................. 9
2.2.1 Revenue and Operating Profit...................................................................................................................... 9
2.2.2 Asset and Liabilities ................................................................................................................................... 10
2.3 Competitive Benchmarking ............................................................................................................................ 11
3 Mergers & Acquisitions and Partnerships ........................................................................................... 12
3.1 M&A and Partnerships Strategy ..................................................................................................................... 12
4 Recent Developments ........................................................................................................................... 14
5 SWOT Analysis ...................................................................................................................................... 17
5.1 SWOT Analysis - Overview ............................................................................................................................ 17
5.2 Strengths ....................................................................................................................................................... 17
5.3 Weaknesses .................................................................................................................................................. 18
5.4 Opportunities ................................................................................................................................................. 18
5.5 Threats .......................................................................................................................................................... 18
6 History .................................................................................................................................................... 20
7 Key Employees ...................................................................................................................................... 22
8 Key Employee Biographies ................................................................................................................... 23
9 Locations and Subsidiaries .................................................................................................................. 24
9.1 Head Office ................................................................................................................................................... 24
9.2 Other Locations and Subsidiaries .................................................................................................................. 24
10 Appendix ................................................................................................................................................ 25
10.1 Methodology .................................................................................................................................................. 25
10.2 Ratio Definitions ............................................................................................................................................ 25
10.3 Disclaimer ..................................................................................................................................................... 29
___________________________________________________________________________________________
ImmunoGen, Inc. - SWOT Profile Page 2
ImmunoGen, Inc.
__________________________________________________________________________________________
List of Tables
Table 1: Major Products and Services ............................................................................................................................. 6
Table 2: Key Ratios - Annual ........................................................................................................................................... 7
Table 3: Key Ratios - Interim ........................................................................................................................................... 8
Table 4: Key Capital Market Indicators ............................................................................................................................ 8
Table 5: History ............................................................................................................................................................. 20
Table 6: Key Employees ................................................................................................................................................ 22
Table 7: Key Employee Biographies .............................................................................................................................. 23
Table 8: Locations ......................................................................................................................................................... 24
___________________________________________________________________________________________
ImmunoGen, Inc. - SWOT Profile Page 3
ImmunoGen, Inc.
__________________________________________________________________________________________
List of Figures
Figure 1: Revenue and Operating Profit ........................................................................................................................... 9
Figure 2: Financial Position ........................................................................................................................................... 10
___________________________________________________________________________________________
ImmunoGen, Inc. - SWOT Profile Page 4
ImmunoGen, Inc.
__________________________________________________________________________________________
1 Business Analysis
1.1 Company Overview
ImmunoGen, Inc. (ImmunoGen) is a biopharmaceutical company specialized in the development of anticancer
therapeutics. The company’s TAP technology uses monoclonal antibodies to produce proprietary cancer-cell killing agents
to tumor cells. Its TAP technology is designed to deliver the creation of well-tolerated anticancer products. The company
also licenses TAP technology to various other companies including Amgen, Lilly, Bayer HealthCare, Biotest, Novartis,
Roche and Sanofi, which use its proprietary antibodies to specific targets. As of June 30, 2012, the company had a
patent portfolio of 381 issued patents and 438 pending patent applications. ImmunoGen is headquartered in Waltham,
Massachusetts, the US.
1.2 Business Description
ImmunoGen develops targeted therapeutics to treat cancer with its competency in the areas of cancer biology,
monoclonal antibodies and potent cytotoxic or cell-killing agents. The company develops anticancer therapeutics using
Targeted Antibody Payload (TAP) technology.
The company operates in a single reportable business segment: discovery of monoclonal antibody-based anticancer
therapeutics.
ImmunoGen developed a proprietary product development technology, Targeted Antibody Payload (TAP) to enhance the
anticancer activity of monoclonal antibodies. This technology may use antibodies with significant anticancer activity
including trastuzumab for the achievement of enhanced anticancer activity. The company also developed a proprietary
cell-killing agent by using TAP technology, called maytansinoid cancer-cell killing agents to interfere in the activity of
Tabulin to affect the successful cell division.
The company focuses extensively on research and development (R&D) operations, as a result of which, it developed a
pipeline of therapeutics for the treatment of cancer. The company develops Trastuzumab-DM1 as its lead product
candidate for treatment of Breast cancer and Gastric cancer in phase III and Phase II of clinical development respectively.
The phase I c